Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Active, not recruiting · NCT04713982 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-05 | NCT04713982 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Teva Branded Pharmaceutical Products R&D, Inc. | 1 |
| Vanderbilt University Medical Center | 299 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Vanderbilt University Medical Center | Nashville | United States | 427 |